Collegium Pharmaceutical Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF1934 For the quarterly period endedJune 30,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF1934 Collegium Pharmaceutical,Inc. (Exact name of registrant as specified in its charter) (781)713-3699(Registrant’s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorterperiod that the registrant was required to submit such files).Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer◻Non-accelerated filer◻Smaller reportingcompany☐Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No⌧ As of July 31, 2025, there were31,502,127shares of Common Stock, $0.001 par value per share, outstanding. TABLE OF CONTENTS PARTI—FINANCIAL INFORMATION Item1.Condensed Consolidated Financial Statements (Unaudited)4Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations35Item3.Quantitative and Qualitative Disclosures About Market Risk45Item4.Controls and Procedures45 PARTII—OTHER INFORMATION Item1.Legal Proceedings46Item1A.Risk Factors46Item2.Unregistered Sales of Equity Securities and Use of Proceeds66Item3.Defaults Upon Senior Securities66Item4.Mine Safety Disclosures66Item5.Other Information67Item6.Exhibits67Signatures68 Forward-Looking Statements Statements made in this quarterly report on Form 10-Q (“Quarterly Report”) that are not statements of historical or currentfacts, such as those under the heading “Management’s Discussion and Analysis of Financial Condition and Results ofOperations,” are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements discuss our current expectations and projections relating to our financial condition, results ofoperations, plans, objectives, future performance and business. These statements may be preceded by, followed by orinclude the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “outlook,” “plan,” “potential,”“project,” “projection,” “seek,” “may,” “could,” “would,” “should,” “can,” “can have,” “likely,” the negatives thereof andother words and terms of similar meaning. Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees ofperformance. You should not place undue reliance on these statements. We have based these forward-looking statements onour current expectations and projections about future events. Although we believe that our assumptions made in connectionwith the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will proveto be correct. You should understand that the following important factors could affect our future results and could cause those results orother outcomes to differ materially from those expressed or implied in our forward-looking statements:●our ability to commercialize and grow sales of our products; ●our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/orwarnings in the label of an approved product;●the size of the markets for our products, and our ability to service those markets;●the success of competing products that are or become available;●our ability to obtain and maintain reimbursement and third-party payor contracts with favorable terms for ourproducts;●the costs of commercialization activities, including marketing, sales and distribution;●the rate and degree of market acceptance of our products;●changing market conditions for our products;●the outcome of any patent infringement, opioid-related or other litigation that may be brought by or a